Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France

COVID Clinical Trial

— INCOVPED  

Official title:

Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04336761
• Other study ID #: 2020_21
• Secondary ID: 2020-A00811-38
• Status: Completed
• Start date: April 15, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: March 2021
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection. It is estimated that the child could be asymptomatic or pauci-symptomatic carrier and thus be vector of the disease. For this reason, measures have been taken to close schools and contain populations in a large number of countries, including France. However, there are no data on the prevalence of COVID-19 in children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 901
• Est. completion date: January 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• 1st Line Consultation in Pediatric Emergencies

• All reasons for consultation during working hours

• Informed and written consent of a parent holder (only 1 authorized companion) and a child of understanding age

Exclusion Criteria:

• Refusal of participation by parents/child of decision age

• No membership of a social security scheme (beneficiary or entitled)

• No understanding of French

Related Conditions & MeSH terms

• Coronavirus
• COVID
• Emergencies
• Infection Viral
• Virus Diseases

Intervention

Diagnostic Test:
• nasopharyngeal swab
Data collection and nasopharyngeal swab

Locations

Country	Name	City	State
France	CH Louis MOURIER	Colombes
France	Hôpital Jeanne de Flandres, CHU	Lille
France	Hôpital Mère Enfant CHU	Nantes
France	Hôpitaux Pédiatriques de Nice CHU-Lenval	Nice
France	Hôpital des enfants - CHU	Toulouse
France	CHU de Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of positivity of COVID-19 virus measured by rt-PCR		At 28 days
Secondary	Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients	children admitted to pediatric emergencies for respiratory signs; Children hospitalized as a result of travelling to pediatric emergency departments for respiratory signs; Respiratory asymptomatic children admitted to pediatric emergencies	at the end an average 28 days
Secondary	Respiratory signs of children tested within 28 day		through study completion, an average 28 days
Secondary	Percentage of children hospitalized tested within 28 day		through study completion, an average 28 days
Secondary	Contact frequency	the degree of relationship with these contacts and the time spent in contact with them within 24 hours before emergency	At inclusion
Secondary	Prevalence of positivity of other respiratory viruses measured by rt-PCR		at 28 days